NEW YORK, May 16, 2024 (GLOBE NEWSWIRE) — FMW Media Works’ New to The Street televised enterprise present will characteristic Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) ($TELO) (“Company”), a pre-clinical stage pharmaceutical firm, targeted on its TELOMIR-1 drug that would reverse age-related frequent ailments.

New to The Street’s TV anchors will interview Telomir Pharmaceuticals Inc.’s administration workforce, introducing and discussing the Company’s improvement of its novel TELOMIR-1 drug, designed to have an effect on age reversal. Each filmed phase will air as sponsored programming on Bloomberg TV and the FOX Business Network.

The New to The Street’s social media workforce and tv community companions will re-share media content material, making a platform to extend consciousness about TELO. All broadcasted exhibits will stream on the New to The Street web site, newtothestreet.com. On a schedule, present previews and industrial adverts will air on the present’s TV platforms. Digital adverts will stream on New to The Street’s billboard platform all through New York City.

The Company is within the pre-clinical stage of testing its TELOMIR-1 drug, the first-of-its-kind potential therapy for age-related irritation circumstances related to osteoarthritis and hemochromatosis. TELO’s administration and scientists consider its small molecule TELOMIR-1 drug might turn into an enzyme inhibitor of key important metals whereas lengthening the DNA’s telomere caps. With enzyme exercise reductions within the physique’s metabolism of metals like , zinc, and iron, TELOMIR-1 might turn into a viable therapy for a lot of ailments, together with some types of most cancers.

Chris Chapman, M.D., the Co-founder, Chairman, and Chief Executive Officer of Telomir Pharmaceuticals, Inc., states, “I’m excited to work with the highly professional  experts at New to The  Street while they begin to market our Company through their national TV media network. This opportunity will provide widespread exposure for the Company, allowing us to tell our corporate story and discuss the research and development of TELOMIR-1. A larger percentage of the population has age-related diseases, and I’m looking forward to explaining the DNA science behind our novel drug and updating viewers about our clinical trials.”

Upon profitable FDA approval, TELOMIR-1 may very well be the primary drug to market to reverse ageing and age-related irritation points successfully.

The Company’s administration and Board of Directors are a extremely educated and  profitable workforce with years of medical, scientific,  administrative, monetary, and regulatory experience.

Vince Caruso, Founder, CEO, and Producer at New to The Street, states, “Most people are concerned about their health and wellbeing. Anything that reduces aging or age-related illnesses will surely catch the attention of many, including our New to The Street viewers. Telomir Pharmaceuticals, Inc.’s research and development of its novel TELOMIR-1 seeks to cure some of humankind’s most common diseases. As the Company proceeds with its FDA clinical trials, we anticipate great interviews and updates from TELO’s management team.”

New to The Street’s TV interviews with Telomir Pharmaceuticals, Inc.’s (NASDAQ: TELO) administration, airings as sponsored programming on Bloomberg TV and the Fox Business Network, “To Be Announced.”

About Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) ($TELO)

Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) ($TELO) is a pre-clinical-stage pharmaceutical firm targeted on the event and commercialization of Telomir-1 as the primary novel small molecule to elongate the DNA’s protecting telomere caps to reverse age-related circumstances probably. Telomeres are the protecting finish caps of a chromosome made up of DNA sequences and proteins. As people age, telomeres shorten, with metallic reactivity accelerating the method, which will increase the prospect of contracting a number of degenerative and age-related ailments. Telomir’s aim is to develop and commercialize Telomir-1 (which is proposed to be dosed orally) for hemochromatosis (iron overload) and finally post-chemotherapy restoration and a broader vary of different age-related inflammatory circumstances resembling osteoarthritis – https://telomirpharma.com/.

About  New to The Street:

New to The Street is an FMW Media manufacturing that operates one of many longest-running US and International sponsored and syndicated Nielsen-rated programming tv manufacturers, “New to The Street.” Since 2009, New to The Street has run biographical interview phase exhibits throughout main U.S. tv networks. The Nielsen-rated and sponsored broadcast programming platform reaches tens of millions of properties within the US and worldwide markets. FMW’s New to The Street present seems on Bloomberg and the FOX Business Network as sponsored programming. FMW can be one of many nation’s largest consumers of linear tv, lengthy and short-form paid programming – https://newtothestreet.com/.

Forward-Looking Statements Disclaimer:

This press launch accommodates forward-looking statements inside Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. In some circumstances, you’ll be able to establish forward-looking statements by the next phrases: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would,” or the detrimental of those phrases or different comparable terminology. However, not all forward-looking statements include these phrases. Forward-looking statements don’t assure future efficiency or outcomes and won’t essentially be correct indications of when such efficiency or outcomes are achieved. Please check with the general public firm filings archived on the Securities and Exchange Commission at www.sec.gov.

CONTACT:

FMW Media Contact: Monica Brennan monica@NewtoTheStreet.com 1-917-330-2564

Telomir Pharmaceuticals information@Telomirpharmaceuticals.com https://telomirpharma.com/ (813) 864-2558

A photograph accompanying this announcement is offered at https://www.globenewswire.com/NewsRoom/AttachmentNg/a9c4998f-e54b-45b6-b239-4a642f4a0447

MoneyMaker FX EA Trading Robot

powered by qhost365.com

Investing.com